Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Craig Allred

Showing results (41-50 of 92) with videos related to

Pageof 10
Sort By:
Breast Cancer Research and Treatment|November 4, 2005
Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancerSyed K Mohsin, D Craig Allred, C Kent Osborne, et al.
American Journal of Clinical Pathology|February 26, 2011
Fixation time does not affect expression of HER2/neuJeffrey D Goldsmith, D Craig Allred, Mary Beth Beasley, et al.
The Journal of Steroid Biochemistry and Molecular Biology|October 19, 2006
Steroid receptor coactivator 2 is essential for progesterone-dependent uterine function and mammary morphogenesis: insights from the mouse--implications for the humanAtish Mukherjee, Paula Amato, D Craig Allred, et al.
Development (Cambridge, England)|February 9, 2007
Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasiaRicardo C Moraes, Xiaomei Zhang, Nikesha Harrington, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 23, 2002
Biological and genetic properties of the p53 null preneoplastic mammary epitheliumDaniel Medina, Frances S Kittrell, Anne Shepard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinaseM Carolina Gutierrez, Simone Detre, Stephen Johnston, et al.
Cancer Research|May 17, 2003
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parametersSuzanne A W Fuqua, Rachel Schiff, Irma Parra, et al.
Breast Cancer Research and Treatment|October 26, 2005
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapiesMichelle D Martin, Susan G Hilsenbeck, Syed K Mohsin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolutionD Craig Allred, Yun Wu, Sufeng Mao, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 26, 2005
Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese womenHazel B Nichols, Amy Trentham-Dietz, Richard R Love, et al.
Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
Breast Cancer Research and Treatment|November 4, 2005
Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancerSyed K Mohsin, D Craig Allred, C Kent Osborne, et al.
American Journal of Clinical Pathology|February 26, 2011
Fixation time does not affect expression of HER2/neuJeffrey D Goldsmith, D Craig Allred, Mary Beth Beasley, et al.
The Journal of Steroid Biochemistry and Molecular Biology|October 19, 2006
Steroid receptor coactivator 2 is essential for progesterone-dependent uterine function and mammary morphogenesis: insights from the mouse--implications for the humanAtish Mukherjee, Paula Amato, D Craig Allred, et al.
Development (Cambridge, England)|February 9, 2007
Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasiaRicardo C Moraes, Xiaomei Zhang, Nikesha Harrington, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 23, 2002
Biological and genetic properties of the p53 null preneoplastic mammary epitheliumDaniel Medina, Frances S Kittrell, Anne Shepard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinaseM Carolina Gutierrez, Simone Detre, Stephen Johnston, et al.
Cancer Research|May 17, 2003
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parametersSuzanne A W Fuqua, Rachel Schiff, Irma Parra, et al.
Breast Cancer Research and Treatment|October 26, 2005
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapiesMichelle D Martin, Susan G Hilsenbeck, Syed K Mohsin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolutionD Craig Allred, Yun Wu, Sufeng Mao, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 26, 2005
Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese womenHazel B Nichols, Amy Trentham-Dietz, Richard R Love, et al.
Pageof 10